Janus Living heads into September with a notable split: short sellers have stepped up their positioning sharply over the past month, even as analysts across the Street have been raising price targets in the wake of strong earnings.
The most striking data point is the rate of short interest accumulation. Shares short climbed roughly 52% over the past month, from around 4.7 million to just over 7.1 million shares — a step-change that arrived in two distinct waves, first around August 10 and again around August 25. That kind of sustained build is worth watching for a Health Care REIT, where short interest rarely moves this fast. The ORTEX short score has drifted higher in tandem, edging from 42.8 to 46.5 over the past two weeks — still mid-range, but directionally consistent with new short conviction entering the name. Against that, the borrow market offers little friction for the bears. Availability remains extremely loose at roughly 1,677% — meaning there are more than sixteen shares available to lend for every one currently borrowed — so there is no squeeze pressure whatsoever in the lending pool. Cost to borrow is running at just 0.43%, well below where it was even a month ago, down roughly 21% over that period. The options market adds a wrinkle: the put/call ratio has jumped to 0.033, nearly at its 52-week high and running almost two standard deviations above its 20-day average of 0.019. That is an extremely low ratio in absolute terms — call volume utterly dominates — but the recent spike toward its own maximum suggests a marginal shift toward defensive positioning in a name that has been almost entirely call-driven all year.
The Street has been unambiguously bullish. Multiple firms raised targets in a tight cluster following the August 5 earnings release. JPMorgan lifted to $34 from $30, Morgan Stanley moved to $31 from $28, and RBC moved to $34 from $30 — all maintaining positive ratings. More recently, Wells Fargo lifted to $35 this week, Barclays moved to $34, and Scotiabank pushed its target to $31. The mean consensus target is $33.67 against a current price of $30.90, implying around 9% upside. Bulls point to an estimated 20% increase in core earnings through 2027 and 2028, driven by strong organic growth in life plan communities and RIDEA structures that give the company more direct exposure to cash flow. Bears counter with a sharper argument: that seniors housing fundamentals are deteriorating, that management has flagged caution on capital deployment, and that the stock's implied cap rate of 5.2% sits well below sector averages — making the valuation look stretched relative to healthcare REIT peers. The EV/EBITDA multiple has compressed notably, shedding about 3.1 turns over the past 30 days, suggesting the market is at least partially pricing in that bear view even as targets move higher.
Ownership sits in an unusual configuration. Healthpeak Properties holds 59.8% of shares outstanding and disclosed an 81.6% stake in a Schedule 13G filed in May — a passive, not activist, filing, though the scale of that anchor position is extraordinary and means ordinary float-based short interest metrics are hard to apply directly here. Among active managers, BlackRock added nearly 5.6 million shares as of July 31, Vanguard Capital added roughly 2 million, and Millennium Management built a new position of around 2.7 million shares in the June quarter. Long Pond Capital trimmed by 721,000 shares in the same period — the only notable reduction among the top holders. The insider register is stale, with the last disclosed trades from March 23, when the CEO purchased $2 million worth of stock at $20 alongside several directors — a cluster buy at a level now 55% below the current price.
What to watch is whether the short interest build continues at this pace into September or plateaus — and whether management's next public commentary on capital deployment provides the clarity that currently divides bulls and bears on the fundamental outlook.
See the live data behind this article on ORTEX.
Open JAN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
